glp-1 vision loss Receptor Agonists and risk Emerging Concerns: GLP-1 Modulators and

Clinical relevance

doi:10.32474/OAJCAM.2023.05.000203

Before starting Wegovy , inform your healthcare provider if you have: History of pancreatitis or gallbladder disease Pre-existing gastrointestinal conditions including inflammatory bowel disease or diverticular disease Severe gastrointestinal disease If you are pregnant, breastfeeding, or planning pregnancy (Wegovy must be stopped at least 2 months before planned conception) Regular follow-up with your prescribing clinician is essential to monitor treatment response, manage side effects, and ensure the medication remains appropriate for your individual circumstances

Warshaw ML et al

BARBER: So do you know when we might have a decision from the FDA

2011 Nov 15;15(10):2779-811